Targeting α-Synuclein The Next Frontier in Parkinson’s Therapy Abstract Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting an estimated 10 million individuals worldwide. Its prevalence is expected to rise substantially with population aging, creating an expanding clinical and socioeconomic
Tag: α-synuclein protein
